Rapid7 (RPD) PT Raised to $40 at Susquehanna
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street dips on hot inflation data ahead of Nvidia earnings
- Oil rises as investors weigh Hormuz talks
- Meta to pay up to $16.68 billion in mass social media settlement
- Anthropic agrees to $45bn cloud computing deal with Nscale - report
- Citi sees an opportunity in Oracle after ’one of the most extreme’ stock drawdowns
- Boston Scientific discloses cybersecurity incident causing global disruption
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Rapid7 (RPD) PT Raised to $40 at RBC Capital
August 7, 2018 8:08 AM EDTRBC Capital raised its price target on Rapid7 (NASDAQ: RPD) to $40.00 (from $38.00) while maintaining an Outperform rating following results.
Analyst Matthew Hedberg said momentum continues to build as Rapid7 steadily executes and even accelerates the recurring revenue transition.
... MoreRapid7 (RPD) PT Raised to $42 at Stifel
August 7, 2018 7:36 AM EDTStifel raised its price target on Rapid7 (NASDAQ: RPD) to $42.00 (from $36.00) while maintaining a Buy rating.
... MoreRapid7 (RPD) PT Raised to $32 at Morgan Stanley
August 7, 2018 7:13 AM EDTMorgan Stanley raised its price target on Rapid7 (NASDAQ: RPD) to $32.00 (from $30.00) while maintaining a Equalweight rating.
... MoreRapid7 (RPD) PT Raised to $38 at KeyBanc
August 7, 2018 4:09 AM EDTKeyBanc raised its price target on Rapid7 (NASDAQ: RPD) to $38.00 (from $35.00) while maintaining a Overweight rating.
... MoreRapid7 (RPD) PT Raised to $37 at Barclays
August 7, 2018 3:56 AM EDTBarclays raised its price target on Rapid7 (NASDAQ: RPD) to $37.00 (from $36.00) while maintaining a Overweight rating.
... MoreAfter-Hours Stock Movers 08/06: (VCEL) (TWLO) (ALSK) Higher; (GEMP) (ZG) (MXWL) Lower (more...)
August 6, 2018 6:10 PM EDTToday's After-Hours Movers
Gemphire Therapeutics Inc. (NASDAQ: GEMP) 21.7% LOWER; announced that the U.S. Food and Drug Administration (FDA) has requested that the Company produce data from a sub-chronic toxicology study to provide information to support lifting the partial clinical hold on gemcabene with respect to clinical trials of longer than six months in duration. The FDA also informed the Company that the End of Phase 2 meeting, and consequently the initiation of Phase 3 trials investigating gemcabene in dyslipidemia indications and long-term safety exposure trials needed for registration,... More
Rapid7, Inc. (RPD) Tops Q2 EPS by 6c, Revenues Beat; Offers FY18 EPS/Revenue Outlook
August 6, 2018 4:13 PM EDTRapid7, Inc. (NASDAQ: RPD) reported Q2 EPS of ($0.13), $0.06 better than the analyst estimate of ($0.19). Revenue for the quarter came in at $58.4 million versus the consensus estimate of $55.14 million.
Rapid7 had a great second quarter, with strong performance around the world and across our solutions, said Corey Thomas, President and CEO of Rapid7. For the fourth quarter in a row, ARR growth accelerated, reaching 44%, driven by new customer growth, upsells and cross-sells, and the success of our shift... More
